MedPath

The Impact of Modified Wheat Bran on Carbohydrate Fermentation in the Colon in Healthy and Obese Subjects

Phase 1
Completed
Conditions
Healthy
Obese
Interventions
Dietary Supplement: Wheat bran
Dietary Supplement: Placebo
Registration Number
NCT02796989
Lead Sponsor
KU Leuven
Brief Summary

During this project the effect of modified wheat bran on colon health and systemic health will be evaluated in a long-term intervention study in healthy and obese subjects.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Aged between 18 and 65 years old
  • BMI between 18 and 25 kg/m² OR higher than 30 kg/m²
  • Regular diet
  • Not dieting
Exclusion Criteria
  • Use of antibiotics in the month preceding the study
  • Diabetes Type 1 or 2
  • Abdominal surgery (except from appendectomy)
  • Use of medication that affects the gastrointestinal tract during the last 2 weeks prior to the study including spasmolytics, anti-diarrhoea medication, anti-constipation medication
  • Use of pre- or probiotic supplements in the month preceding the study
  • Chronic gastrointestinal diseases, such as inflammatory bowel disease (Crohn's disease, ulcerative colitis), irritable bowel disease...
  • Pregnancy or lactation
  • Blood donation in the last 3 months
  • Abnormal Hb-level (Standard range between 14 and 18 g/dL for men and between 12 and 16 g/dL for women)
  • Participation in clinical studies involving radiation exposure in the past year

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Healthy - Wheat BranWheat branWheat bran 20 g each day
Healthy - PlaceboPlaceboPlacebo 20 g each day
Obese - Wheat branWheat branWheat bran 20 g each day
Obese - PlaceboPlaceboPlacebo 20 g each day
Primary Outcome Measures
NameTimeMethod
The incremental plasma short-chain fatty acid concentrations will be measured using GC-FID after an intervention with wheat bran/placebo1 month
Secondary Outcome Measures
NameTimeMethod
Total gastrointestinal transit time1 month
Gut permeability using 51-Cr-EDTA1 month
Changes in gut microbiota before and after the intervention using 16S rRNA sequencing1 month
Changes in glucose levels (mg/dL)1 month
Changes in cholesterol levels (mg/dL)1 month
Changes in free fatty acids levels (mmol/L)1 month
Changes in triglyceride levels (mg/dL)1 month
Changes in insulin levels (pmol/L)1 month
Changes in metabolite patterns in the feces before and after the intervention using gas chromatography coupled to mass spectrometry1 month

Trial Locations

Locations (1)

KU Leuven

🇧🇪

Leuven, Vlaams-Brabant, Belgium

© Copyright 2025. All Rights Reserved by MedPath